The t(1;19) translocation that characterizes 25% of pediatric pre-B cell acute lymphoblastic leukemias (pre-B ALL} produces a chimeric gene, joining 5' sequences that encode a transcriptional activator domain of E2A with 3' sequences that, in part, encode a homeo box domain of a new gene called pbxl. Two E2A-pbxl transcripts have been cloned. They encode the putative fusion proteins, p85 E2A-pbxl and p77 E2A-pbxl, which differ in Pbxl sequences alone, containing unique carboxyl termini whose sequences diverge after the Pbxl homeo box. In this study, an antiserum to Pbxl was used to investigate the identity and abundance of E2A-Pbxl fusion proteins in both the pre-B ALL cell line, 697, and in cryopreserved leukemic bone marrow cells, obtained from six children with t(1;19)-positive pre-B ALL. Five species of E2A-Pbxl proteins were identified in all cells containing t(l;19), two of which were indistinguishable from in vitro-translated p85 E2A-pbxl and p77 E2A-pbxl. To assess the biological properties of p85 E2A-pbxl and p77 F2A-pbxl in fibroblasts, the cDNAs encoding these proteins were cloned into retroviral vectors, and each was introduced into NIH-3T3 cells. Both p85 E2A-vbxl and p77 E2A-pbxl are localized in the nucleus, and expression of either resulted in malignant conversion of NIH-3T3 cells as assayed by tumor formation in nude mice. When scored by focus formation, density-independent growth, and growth in agar assays, p77 E2A-pbxt was a much more potent transforming protein than was p85 E2A-rbX~. Because subtle mutations in p85 E2A-pbxl converted its transforming activity into that of p77 E2A-pbxt, we suggest that a sequence within the unique carboxyl terminus of p85 E2A-pbxl serves to negatively regulate its biochemical activity.
The binding of potential transcription factors to specific DNA sequences in the immunoglobulin heavy-and light-chain enhancers was first observed by footprinting studies both in vitro and in vivo Ephrussi et al. 19851 . The KE2 DNA sequence motif, contained in the immunoglobulin K light-chain enhancer, was subsequently shown to be important in the transcriptional activation of this gene, because mutation of this sequence diminishes the strength of the K enhancer [Sen and Baltimore 1986; Lenardo et al. 1987} . Both the E2A and ITF-2 genes encode proteins that bind the KE2 motif, each behaves as a transcriptional activator (Murre 1989a; Henthom et al. 1990) , and together they share considerable amino acid identity. Two domains in the E2A protein have been characterized--an amino-terminal domain that activates transcription and a carboxyterminal domain involved in sequence-specific DNAbinding and dimer formation with other cellular transcription factors {Murre 1989a, b; Davis et al. 1990; Henthom et al. 1990; Voronova and Baltimore 1990} . In contrast to the normal role of E2A in transcriptional regulation, the occurrence of a mutant form of E2A in human pre-B ALL {Kamps et al. 1990} suggests that it may also be involved in aberrant transcription and leukemic tumorigenesis.
The breakpoint of the t( 1; 19)( q23;p 13.3) translocation, which is evident cytogenetically in 25% of pediatric pre-B ALL (Carroll et al. 1984; Williams et al. 1984} and is associated with a poor prognosis iCrist et Raimondi et al. 1990} , has been mapped within the E2A gene, which resides at 19p13.3 (Mellentin et al. 1989) . Using an E2A cDNA probe, chimeric cDNAs containing sequences from both E2A and a second uncharacterized gene, previously designated prl, but now renamed pbxl, were isolated from the t{1;19}-positive pre-B ALL cell lines, 697 {Kamps et al. 19901 and SUP-B27 (Nourse et al. 1990) . prl was renamed pbxl to avoid confusion with the prolactin locus, which is also designated PRL. The fusion proteins predicted by E2A-pbxl transcripts contain the amino-terminal trans-activation domain of E2A but have the carboxy-terminal DNA-binding and dimerization domain of E2A replaced with a homeo box encoded by pbxl. The sequence of the Pbxl borneo box is not identical to that of any other but does contain a remarkable 19 of 27 amino acid identity in its carboxy-terminal half to that of the yeast MATal protein, a transcription factor that, together with the MATcxl protein, represses haploid-specific gene expression and allows sporulation to occur (Miller et al. 1985; Nasmyth and Shore 1987) . The reciprocal translation product, composed of the 5' portion of pbxl and the 3' portion of E2A, is not involved in the development of t(1;19)-containing pre-B ALL because it is contained on the der (1) chromosome, which is lost from the leukemic cells in >80% of cases examined (Mellentin et al. 1989 ) and because transcriptional regulation of this locus, when it remains intact, is mediated by the pbxl promoter, which is silent in pre-B and mature B cells (Kamps et al. 1990; Nourse et al. 1990 ). The domain structure of E2A-Pbxl proteins suggests that their potential contribution to the development of pre-B ALL is the activation of Pbxl-responsive genes by the E2A trans-activation domain in either pre-B cells or their progenitors.
Two E2A-pbxl transcripts, likely the result of alternative splicing, have been cloned and sequenced (Kamps et al. 1990; Nourse et al. 1990 ). They are designated type I and type II and encode the putative fusion polypeptides, p85 ExA-Pbxl and p77 E2A-Pbxl, which differ at their carboxy-terminal ends. The goals of this study were to identify the forms of E2A-Pbx 1 proteins contained in leukemic cells having the t(1;19) translocation and investigate the transforming potential of these fusion proteins in NIH-3T3 fibroblasts. We find that a family of E2A-Pbxl proteins, including p85 E2A-vbxl and p77 E2A-Pbxl, arise as a consequence of the t(1;19) translocation, and that E2A-Pbxl proteins are oncoproteins whose specific activities appear dependent on their unique carboxyl termini.
R e s u l t s

Antibodies to Pbxl bind five species of E2A-Pbxl fusion proteins
Previously (Kamps et al. 1990} , we reported that 697 cells, which contain the t(1; 19) translocation, contain a new, 90-kD, E2A-related polypeptide, in addition to normal E2A proteins. This novel protein was predicted to be the translocation product of the cloned type I E2A-pbxl fusion transcript. At this time, the putative 77-kD product of the type II E2A-pbxl transcript was not identified in immunoprecipitates from 697 cells using antibodies reactive with E2A. To separate E2A-Pbxl fusion proteins from normal E2A proteins in 697 cells and then compare their primary structures to that of in vitrotranslated p85 E2A-vbxl and p77 E2A-pbxl, a rabbit antiserum was raised against Pbxl {see Materials and methods) and used to isolate Pbxl-containing polypeptides from 697 cells by immunoprecipitation. Five proteins were E2A-Pbxl chimeric homeo box gene and leukemia immunoprecipitated by the anti-Pbxl serum (Fig. 1, lane  6) , two of which comigrated with in vitro-translated p77 E2^-Pbxl and p85 E2A-pbxl (lanes 7 and 8). None of the five proteins was immunoprecipitated from Nalm-6 cells, a human pre-B cell line that lacks the t( 1; 19) translocation (lane 3) or by a nonspecific antiserum to the retinoblastoma protein, p110 Rb {lanes 1 and 4). Although the two proteins that comigrated with in vitro-translated p85 E2A-pbxl and p77 E2A-pbxl are detectable in immunoprecipitates from 697 cells using an antiserum to E2A, the remaining three were obscured by polypeptides reactive with antibodies to E2A (lane 5} and, therefore, were not observed earlier. These results demonstrate that a family of at least five proteins, expressed specifically in 697 cells, are immunoprecipitated by anti-Pbxl serum because they either contain Pbxl, are associated with a Pbxl-containing protein, or cross-react with anti-Pbxl antibodies.
To distinguish among these possibilities, a partial proteolysis assay using Staphylococcus aureus V8 protease was developed {Cleveland et al. 1977) . A distinctive pattern of peptides resulted from partial proteolysis of p85 E2A-Pbxl and p77 E2A-Pbxl with 5, 15, or 50 ng of S.
aureus V8 protease, followed by resolution by polyacrylamide gel electrophoresis {PAGE}. The pattern obtained by digestion with 50 ng of protease was used to typify E2A-Pbxl proteins and to discriminate between Nalm-6 697
I 2 3 4 5 6 7 8 Figure 1 . Immunoprecipitation with antibodies to E2A and Pbxl. Nalm-6 cells, a human pre-B cell line that does not contain the t( 1; 191 translocation, and 697 cells, which contain the translocation, were labeled biosynthetically with [aSS]methionine and subjected to immunoprecipitation with a control antiserum against the retinoblastoma protein {designated Rbl, an antiserum against E2A [designed E2AI, and an antiserum to Pbxl (designated Pbxl). p77 E2A-Pbxl and p8S E2A-Pbxl markers were translated from RNA, transcribed in vitro from the type H and type I E2A-pbxl cDNAs, and analyzed in the last two lanes.
The mobility of p110 ga, p85 E2A-pbxl, and p77 E2A-pbxt are indi- p85 E2A-Pbxl and p77 E2A-vbxl (Fig. 2B) . In vitro-translated p85 E2a-vbxl and p77 E2A-vb'l each contained major proteolytic fragments of 46, 33, and 20 kD (peptides A, B, and D, respectively); however, only p85 E~a-vbxl contained a major polypeptide of -2 4 kD (peptide C). This fragment is most likely derived from the carboxyl terminus of p85 E2A-vbxl, which contains an additional three methionines not present in p77 E2A-vbxl (Fig. 2A} . Proteins precipitated from 697 cells with antibodies to Pbxl were given numerical assignments indicated in Figure 2C . The partial proteolytic pattern produced by p85 E2A-vbxl translated in vitro was identical to the major protein precipitated from 697 cells by antibodies to Pbxl (Fig. 2D, lanes 1 and 2) sequently, p77 E2A-vbxl is also a bona fide E2A-Pbxl protein in 697 cells. Finally, bands 1, 3, and 5 yielded a proteolytic pattern containing the diagnostic C peptide of p85 E2A-vbx*, and overall, that was very similar to the pattern of p85 E2a-vbx]. A slightly larger A peptide was generated by bands 3 and 5, suggesting that these proteins are more closely related to each other than to the other E2A-Pbxl proteins. We will refer to the proteins that comprise bands 1, 3, and 5 and p87 E2A-vbxl, p83 E2A-pbxl, and p72 E2A-Pbxl, respectively.
Each of the five E2A-Pbxl proteins are present in bone marrow lymphoblasts from patients with t(1; 19)-containing pre-B ALL
It was of interest to determine whether the five E2A-Pbxl proteins are contained in primary tumor cells in approximately the same abundance as in 697 ceils and thereby exclude the possibility that any one of the forms may have arisen uniquely in 697 cells during their establishment in tissue culture. Bone marrow aspirates comprised of >85% leukemic cells were obtained from six children with t{1;19} pre-B ALL. The identity of Pbxlcontaining proteins in these cells was determined by two methods. First, ceils were labeled biosynthetically with [aSS]methionine, and Pbxl-containing proteins were isolated from cellular extracts by immunoprecipitation {Fig. 3A). Proteins that bound nonspecifically during immunoprecipitation were identified by the use of an anti-Rb serum and are illustrated in the first of each set of lanes.
The five forms of E2A-Pbxl proteins were found in cells from patients TU, JO, and PI. Forms 1, 2, and 3 were found in cells from patients PA, CH, and RE, but forms 4 and 5 were obscured by the presence of background bands, probably monoclonal IgM heavy chain. To confirm the results of immunoprecipitation analysis and avoid the problem of comigrating nonspecific proteins, an immunoblot analysis was developed, utilizing affinity-purified anti-Pbxl immunoglobulins and total cellular proteins from lymphoblasts derived from each of the same patients {Fig. 3B). Immunoblot analysis represented a rapid and accurate diagnostic technique for the identification of E2A-Pbxl proteins. In this analysis, no proteins were stained in extracts from the control cell line, Nalm-6, in the region containing E2A-Pbxl proteins in 697 cells (lanes designated Nalm-6 and 697). Each of the cells from patients contained all of the same five species of E2A-Pbxl proteins as were found in 697 cells, and most are visible in Figure 3B . In particular, forms 4 and 5 were apparent in PA, CH, and RE. The staining of E2A-Pbxl band 4 was approximately twofold more intense in lysates from 697 cells than in those from patient cells. The fact that all five E2A-Pbxl proteins are observed in all cells containing the t(1; 19) translocation strengthens the suggestion that the breakpoints in E2A and pbxl occur consistently in the same introns, join the same coding exons in the fully processed mRNA, and, therefore, produce the same E2A-Pbxl proteins. We know that the 3' E2A sequences in the E2A-pbxl transcript are 3' sequences of exon 'T' of the E2A gene, and, consequently, the E2A breakpoints lie within the adjacent 3' intron, which is 4 kb in length (Kamps et al. 1990; S.-H. Sun, in prep.) . Because 697 cells contain a fairly accurate representation of both the sizes and abundances of E2A-Pbxl proteins that are observed in lymphoblasts of patients exhibiting t(1; 19)-positive pre-B ALL, they represent an appropriate choice of cells in which to study these proteins. The relative abundances of E2A-Pbxl proteins, most accurately reflected by immunoblot analysis (Fig. 3B , lane 697; Fig. 4B , lane 697}, were the same as observed by immunoprecipitation, in which case 697 cells were labeled biosynthetically for 3 hr {Fig. 1, lane 6, 697 cells; Fig. 2C ). Each analysis suggested that form 2 (p85 Ez^-pb'l) comprises approximately half of all Pbxlcontaining proteins, that form 5 is least abundant, and that forms 1, 3, and 4 are approximately equal and intermediate in abundance. Pulse-chase analysis revealed that the same relative abundance of the major forms of E2A-Pbxl--polypeptides 2-4--is found after only a 30-rain label of 697 cells and that each of these proteins has a half-life of -4 hr. Thus, all E2A-Pbxl proteins are likely to be primary translation products of different transcripts.
Expression of p77 a2A-vb':~, but n o t p85 E2A-Pbxl, induces focus formation in NIH-3T3 cells
The cDNAs encoding p85 E2A-Pbxl and p77 Ez^-Pbxl were each inserted into a retroviral expression vector designated pGD (see Materials and methods), which expresses the neomycin resistance gene (neo) from an internal SV40 promoter, and the inserted cDNA from the 5' viral LTR. Constructs were transfected into NIH-3T3 cells, and cells expressing neo were selected in the presence of G418 (Geneticin). Defective viruses encoding each E2A-Pbxl protein were rescued by superinfection with Moloney murine leukemia virus (MLV), and their titers were assayed by transmission of G418 resistance. Populations of cells, selected for expression of each virus, were shown to contain proteins that comigrated with p85 E2A-Pbxl and p77 E2A-pbxl, translated in vitro (Fig.  4A) . The morphological effects of p8S E2A-Pbxl and p77 E2^-eb'l expression in fibroblasts were analyzed by infection of NIH-3T3-cll0 cells with each virus at a multiplicity of one. After 12 days of growth in normal medium (no selection), many foci of varying sizes formed on monolayers infected with the virus encoding p77 E2^-ebx~ (Fig. 5, photo 3; Fig. 6 , photos 3 and 6}, but only tiny areas of slightly increased cell density formed on monolayers infected by the virus encoding p85 E2A-Pbxl {Fig. 5, photo 2; Fig. 6 , photos 2 and 5). A different subclone of NIH-3T3, NIH-3T3-cl2, developed larger foci after infection by virus encoding p77 E2A-ebxl (Fig. 5, photo 4 ). Therefore, the focus-forming potential of p77 E2^-pbxl is influenced somewhat by clonotypic variations in NIH-3T3. On NIH-3T3 cll0, low multiplicity of infection (1000 neo-forming units/5 × l0 s infected cells) with virus encoding p77 E2A-ebxi produced mostly small foci-containing cells that were not as refractile as those resulting from higher multiplicity of infection. However, when cells were infected at low multiplicity with virus expressing p77 E2A-pBx~ and selected for growth in G418, 40% of NIH-3T3-cll colonies exhibited the transformed, refractile phenotype (data not shown). Therefore, normal cells induced suppression of the transformed phenotype. Three subclones of NIH-3T3 were evaluated for focus formation by virus encoding p85 ExA-Pbxl. All produced the same subtle morphological changes depicted in photos 2 and 5 of Figure 6 .
Mutations in p 8 5 E2A-Pbxl c o n v e r t its behavior to that of p 77 E2A-Pbxl
While cells infected with virus encoding p85 E2A-pbxl were being passaged, large foci reminiscent of those produced by cells containing p77 E2A-pbxl arose after 8-10 weeks. Virus from these isolated foci now induced overt focus formation on unselected NIH-3T3-cll, mimicking the effect of virus encoding bona fide p77 E2A-Pbxl. The identity of E2A-Pbxl protein encoded by these focusforming variants was analyzed from eight clones {Fig. 7A). All eight virus-encoded E2A-Pbxl proteins had molecular masses quite similar to that of p85 E2A-pbxl, and none was identical to p77 ExA-Pbxl. Therefore, subtle mutations in p85 E2A-Pbxl, some of which slightly alter the mobility of p85 E2A-Pbxl, can change its biochemical activity to mimic that of p77 E2A-Pbxl. Because focus-forming variants of p85 E2A-Pbxl were produced by cells productively infected by virus encoding p85 E2A-pbxl, an accurate analysis of the ability of p85 E2A-Pbxl to induce growth in agar and tumors in nude mice could not be performed using these cells. Therefore, nonproducer lines of NIH-3T3 containing p77 E2A-pbxl or p85 E2A-pbxl were generated.
Both p77 E2a-vbxl and p85 ~2a-pbxl are oncoproteins
NIH-3T3-cll cells were infected with helper-free stocks of virus encoding p77 r2n-PbXl or p85 r2A-pb'l {Materials and methods) and selected in G418 for 3 weeks. As shown by immunoblot analysis, these NIH-3T3 cells contained equivalent quantities of p77 r2n-Pb'l and p85 E2A-pbx~ {Fig. 7B) and did not produce virus {<1 G418 resistance unit/10 ml of supernate vs. 2 x 106/ml for producer cells}. After extended passage, no foci formed in cultures of nonproducer cells containing p85 r2n-Pb'~, indicating that the activating mutations that arose in p85 E2A-Pb'~ in cultures containing helper virus occurred during viral replication. Nonproducer NIH-3T3 ceils containing p77 E2A-vbx~ and p85 E2A-vbx~ were therefore used to test additional oncogenic properties of these two E2A-Pbxl fusion proteins. Expression of p85 E2A-Pbxl and p77 E2A-vbx~ in nonproducer cells induced a 5-and 12-fold increase in the density at which cells stopped dividing (Table 1) . Although expression of either p85 E2A-pbxl or p77 E2A-vbxl permitted the growth of NIH-3T3 cells in agar, p77 E~A-vbxt was at least 10-fold more effective than w a s p85 E2A-pbxl (Table 1 ; Fig. 6 , photo 9}. Immunofluorescence analysis revealed that the largest colonies of cells that grew in agar also contained the most E2A-Pbxl protein (data not shown). Tumorigenicity was tested in nude mice by subcutaneous injection of 8 x l0 s cells. Nonproducer cells expressing p77 EzA-vBxl or p85 E2A-Pbxl formed tumors at the site of injection within 6 weeks. Antibodies to Pbxl heavily stained a 77-kD protein on an immunoblot containing protein extract from a tumor that arose after injection of cells expressing p77 F2A-vbxl, indicating that the tumor grew from the introduced cells and was not a host proliferation in resonse to the introduced cells. Normal NIH-3T3 cells were not tumorigenic (Table 1 ) . Therefore, in spite of the different transforming potentials of p77 E2^-vbxl and p85 E2A-vbx~ in cell culture assays, both proteins contribute directly to the oncogenic conversion of NIH-3T3 cells.
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E2A-Pbxl proteins are nuclear
The intracellular location of p85 E2A-r'bxl and p77 E2A-Pbxl was determined by immunofluorescence. Cells expressing both p85 E2A-pbxl and p77 ~a^-vbx~ exhibited nuclear fluorescence that spared the nucleoli (Fig. 8 and data not shown). We estimate the average abundance of each protein in the nucleus of selected populations of NIH-3T3 to be approximately fivefold greater than that in the nuclei of 697 cells, based on Western blot analysis of equivalent amounts of cell extract (Fig. 4 , lanes 697, 3, and 4) and taking into consideration the difference in protein content per cell between fibroblasts and lymphocytes. We were unable to demonstrate strict nuclear localization of E2A-Pbxl proteins in 697 cells, because the lower levels of E2A-Pbxl expression required higher sensitivity, and cytosolic and membrane staining, a small amount of which is evident in the normal fibroblasts in Figure 8 , became prominent features under these conditions.
Normal pbxl transcripts are observed in most tissues in the developing and adult mouse
Transcriptional regulation of pbxl was examined by analysis of the pbxl transcript during mouse development, in 12-, 14-, 16-, and 18-day embryos, as well as in specific adult tissues. The size of pbxl transcripts are heterogeneous, having two major species of 2.2 and 6.8 kb {Fig. 9). The difference in size between the 2.2-and 6.8-kb transcripts of pbxl was essentially the same as for the 3.2-and 8.0-kb fusion transcripts of E2A-pbxl, suggesting that alternate splicing in pbxl accounts for this difference of -4 . 8 kb. Low levels of pbxl expression were detected throughout embryogenesis, as well as in most adult tissues, and pbxl transcripts in lung and brain were approximately twofold more abundant, the 6.8-kb form predominating in both tissues. Expression of pbxl was extremely low in spleen, consistent with our previous observation that pbxl is not expressed in early Analysis was performed on nonproducer populations of NIH-3T3 expressing either p85 r2A-vbxl {designated + 85 E2A-Pxl) or p77 E2A-vbxl {designated +p77E2A-Vbx~). The number of colonies formed in agar was measured from plates seeded with 200,000 cells. The size of tumors formed in nude mice was measured 6 weeks after injection of cells.
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Cold Spring Harbor Laboratory Press on November 6, 2017 -Published by genesdev.cshlp.org Downloaded from transcripts cloned earlier (Kamps et al. 1990~ Nourse et al. 1990} . Partial proteolytic cleavage patterns of the other three polypeptides were related to that of p85 E2A-vbxl, indicating that each of these proteins represents either a post-translation modification of p85 E2A-Pbxl or a highly related protein translated from an alternatively spliced E2A-pbxl mRNA. Because none of the other three forms of E2A-Pbxl proteins was observed in NIH-3T3 cells expressing either p85 E2^-vbxl or p77 r'2A-vbx~, we favor the hypothesis that each additional form results from alternative splicing. The suggestion that alternate splicing produces transcripts encoding these proteins is not unlikely because two different sequences have been found to initiate normal E2A proteins (S.-H. Sun, unpubl.}. In addition, the existence of a second major 8.0-kb transcript in all t(lil9}-containing lymphoblasts examined to date (Mellentin et al. 19891 Kamps et al. 1990~ Nourse et al. 1990 ) suggests that at least one additional variation within the Pbx 1 portion of E2A-Pbxl proteins is also possible.
The fact that p77 E:zA-r'bxl was more transforming than p85 r2A-vbx~ in tissue culture assays and the observation that subtle mutations in p85 r2A-vbx~ dramatically elevate its transforming activity suggest that a biochemical activity of p85 r2A-vbx~ may be regulated by a normal cellular mechanism and that such regulation may require the unique 97-amino-acid carboxyl terminus of p85 E2A-vbx~. If so, alternate splicing would represent a cellular mechanism that generates an activated E2A-Pbxl protein, p77, and might be a method used by normal cells to regulate the activity of endogenous Pbxl.
or mature B or T cells (Kamps et al. 19901 Nourse et al. 19901 . pbxl was also not expressed in adult testes. Therefore, although Pbxl contains a homeo box, its expression pattern suggests that it is neither a tissue-nor a developmental stage-specific transcription factor. Instead, the widespread, low-abundance expression of pbxl indicates that the Pbxl protein performs a more ubiquitous function.
Discussion
In this study we identify five forms of E2A-Pbxl proteins in lymphoblasts having the t(1119} translocation, and characterize the activities of the proteins encoded by two cloned E2A-pbxl cDNAs. Immunoprecipitation and Western blot analysis were used to demonstrate that each of the five forms of E2A-Pbx 1 proteins is contained in both the pre-B ALL cell line, 697, and in lymphoblasts from the marrow of children having t( l il9)-positive pre-B ALL. Immunoblotting with affinity-purified antibodies to Pbxl provided a rapid and sensitive screen for the presence of E2A-Pbxl proteins in t (1119) 
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Although the absolute activities of p85 E~A-Pbxl were lower than those of p77 F' 2A-vbx] , p85 E2A-Pbxl was at least as good as p77 ExA-l'bxl in contributing to the tumorigenic conversion of NIH-3T3, as assayed by tumor formation in nude mice. Therefore, both forms of E2A-Pbxl proteins may well alter the growth or development of pre-B lymphocytes, coincident with acquisition of the t{ 1; 191 translocation.
The transformation potential of E2A-Pbxl proteins may also differ when they are expressed in fibroblasts and pre-B lymphocytes. Because normal pbxl is transcribed in NIH-3T3 fibroblasts but not in pre-B cells, E2A-Pbxl protein would presumably compete for binding DNA with endogenous Pbxl proteins in fibroblasts but would bind unchallenged in pre-B cells. As a result of such competition, more E2A-Pbxl protein might be needed to induce penetrance of the tumorigenic phenotype in fibroblasts than in pre-B cells. The positive correlation between the abundance of E2A-Pbxl protein and the ability of cells to grow as colonies in agar may reflect one example of behavior consistent with such a hypothesis. Our observation that larger loci are formed when NIH-3T3 cells are exposed to higher titers of virus encoding p77 E2A-Pbxl also supports this contention. Examination of the effects of E2A-Pbx 1 expression in pre-B lymphoid cells will be required to further clarify this question.
In an effort tO clarify the effects of p85 E2A-pbxl and p77 E2A-Pbxl in lymphocytes, we expressed each in the IL3-dependent cell lines BA/F3 and LyD-9. Neither protein affected either the absolute or relative dependence of these cell lines on IL3 for growth. Consequently, we conclude that these two E2A-Pbxl proteins do not behave as does BCR-ABL, or activated cytosolic or transmembrane tyrosine protein kinases, whose expression obviates the growth factor dependence of these and similar IL3-dependent cells (Daley and Baltimore 1988; Kipreos and Wang 1988; Pierce et al. 19881 Sherr 1988}. Experiments are now under way to determine whether p85 E2A-pbxl or p77 E2A-PbX] themselves, or in combination with growth factors or other oncoproteins, can induce lymphoid transformation.
The normal pbxl gene is clearly transcribed in many cell types. Major transcripts of 2.2 and 6.8 kb, as well as a variety of intermediate, less abundant forms, were expressed at approximately equal levels in many tissues.
Because pbxl is also expressed in 12-, 14-, 16-, and 18-day embryos with little variation in abundance, we conclude that Pbxl performs a widespread function that is either not required or detrimental to the development of B and T cells. We are now cloning the normal pbxl transcript to determine the size and properties of the aminoterminal domain of Pbxl that is not present in the E2A-Pbxl fusion protein. Immunoprecipitation analysis suggests that a normal Pbx protein may be -42 kD, because an antigen of this size reacts with anti-Pbxl sera in NIH-3"I'3 fibroblasts, but not in pre-B cells {Fig. 4). This would predict that 55 amino-terminal residues of Pbxl are not contained in E2A-Pbxl. However, in our efforts to clone a full-length pbxl transcript, we have cloned a highly related cDNA, denoted pbx2, that is transcribed from a clearly distinct genetic locus and would most likely also react with anti-Pbx antisera. Therefore, we do not know whether the 42-kD protein is Pbxl, Pbx2, or another member of a potentially larger family of Pbx proteins.
Cloning of the 5' end of pbxl will permit us to address two key questions in understanding the biological activity of E2A-Pbxl proteins: Does the E2A amino-terminal domain contribute an active or passive role in the biochemistry of E2A-Pbxl fusion proteins, and must the normal amino-terminal sequences of Pbxl be removed to create a transforming protein? It is possible that the role of E2A in t(l~ 19)pre-B ALL may be simply to induce the production of Pbxl in these cells. Alternatively, the amino-terminal transcriptional activation domain of E2A may be indispensable for transformation-associated properties of E2A-Pbxl proteins. It is also possible that the amino-terminal sequences of Pbxl may repress its activity and would need to be deleted to form an oncoprotein. Although these questions can, in part, be addressed by expression of proteins in NIH-3T3 cells, an animal model involving E2A-Pbxl-mediated leukemogenesis in mice will inevitably be required to evaluate fully the functional domains essential in the induction of pre-B ALL by E2A-Pbxl proteins.
Materials and methods
Production and purification of GST-Pbxl fusion protein
The oligonucleotide, 5'-GTGTTTTGAGAATTCGAGGAGC-CC-3', was used to introduce an EcoRI site 6 nucleotides to the 3' side of the junction between E2A and pbxI sequences in the E2A-pbxl eDNA clone, pBSK:E2A-pbxI-II. The pbxl sequences, now flanked by EcoRI sites, were ligated into the EcoRI site of pGEX-2T (Amrad, Australia), a bacterial vector that expresses cloned cDNAs as glutathione S-transferase (GST) fusion proteins. The resulting GST-Pbxl protein contains 28 kD of Pbxl and has a predicted molecular mass of 56 kD. p56 GsT-Pbxl was isolated from the insoluble fraction of bacterial extracts for immunization {see Preparation of antisera to Pbxl, below) and by adsorption to glutathione agarose (Sigma) and eluted with free glutathione (Sigma] for the purification of soluble p56 GsT-vbxl as specified by Amrad. A majority of p56 GsT-Pbxl was insoluble, but 5% could be isolated as soluble protein. Once purified, the DNA-binding properties of these GST-Pbxl proteins was tested by adsorption to calf thymus DNA-agarose (Sigma), followed by elution with increasing concentrations of salt. A total of 1.3 mg of GST-Pbxl protein was incubated with 0.4 ml of DNA-agarose (containing 1.0 mg/ml of bound DNA) in a total of 3 ml of 50 mM Tris {hydroxymethyl) aminomethane (Tris; pH 7.1}, 100 mM NaCI {TN} with continuous agitation for 2 hr at 4°C. After 2 hr, the resin was allowed to settle in the column, a flowthrough fraction was collected, and the column was washed three times with 1.5 column volumes (CV) of TN. Proteins that bound the DNA were eluted by washing the resin with 1.5 CV of TN containing NaCI concentrations that were increased by 100 mM increments.
Preparation of antisera to Pbxl
Fifty milliliters of bacteria containing the pGEX-2T-pbxl expression plasmid were induced for 2 hr with 100 V.M IPTG, as
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Cold Spring Harbor Laboratory Press on November 6, 2017 -Published by genesdev.cshlp.org Downloaded from specified by Amrad. The bacteria were pelleted by centrifugation, resuspended in 1S ml of 100 mM EDTA, 1% NP-40 (Sigmal, 1% aprotinin (Sigma), and disrupted by sonication. At this point, 90% of the GST-Pbxl fusion protein was contained in the insoluble material. Insoluble GST-Pbxl was isolated by centrifugation at lO, O00g for 10 min at 4°C. The yield of insoluble GEX-Pbxl fusion protein was -1200 lag/50 ml of initial bacterial culture. This pellet was solubilized in 2 ml of SDS containing sample buffer, and the equivalent of 600 vLg of GSTPbxl protein was fractionated by SDS-PAGE, using a gel 2 mm thick. After completion of electrophoresis, GST-Pbxl was visualized as a band of precipitated protein-SDS complexes after incubation in 2.0 M KC1 for 30 min at 4°C. The band was excised and equilibrated in water for 30 min. One-third of this gel slice was emulsified with two volumes of complete Freund's adjuvant and one volume of water. Rabbits were injected with a total of 100 vLg of GST-Pbxl at six intradermal locations on their backs and boosted 4 weeks later using the same protocol with the substitution of incomplete for complete Freund's adjuvant. Four weeks after the first boost, the serum was tested for its ability to immunoprecipitate Pbxl-containing proteins from 697 cells. Each of two rabbits subjected to this protocol produced a titer of anti-Pbxl antibodies by which 1 ~1 of serum was capable of immunoprecipitating all of the five E2A-Pbxl proteins from 5 x 10 6 cells.
Biosynthetic labeling, immunoprecipitation, and partial proteolysis
Both lymphocytes and fibroblasts were labeled biosynthetically with 200 ~Ci of [aSSImethionine (Amersham) for 3 hr in 1 rnl of methionine-free DMEM, containing 20% dialyzed fetal bovine serum and 50 ~M 2-mercaptoethanol. After 3 hr, the cells were washed once in PBS and lysed in 400 ~tl of 50 mM Tris (pH 7.4), 300 mM NaC1, 0.1% NP-40, 1 mM PMSF, 5 mM EDTA, and 1 mM DTT (ELB buffer). Lysates were clarified by centrifugation at 10,000g for 1.5 hr. Portions of this cellular extract were subjected to immunoprecipitation according to published conditions (Sefton et al. 1978} , using ELB buffer for all washes, and analyzed by SDS-PAGE using 10% acrylamide gels with low bis-acrylamide concentrations. Gels were processed using DMSO containing 20% PPO to enhance the signal from radioactive proteins. Partial proteolysis was performed in the gel according to the method of Cleveland et al. (1977) , and peptides were resolved by SDS-PAGE using 20% acrylamide gels with low bis-acrylamide concentrations.
Affinity purification of antisera
A total of 0.75 mg of GST-Pbxl proteins, purified from bacterial extracts by affinity to glutathione-agarose (see Production and purification of GST-Pbxl fusion protein, above) was coupled to 0.4 ml of Affi-gel 10 in 100 mM 3-(N-morpholino)-propanesulfonic acid (MOPS) (pH 7.0) buffer according to the manufacturer's protocol (Bio-Rad). The resin was washed twice at 4°C in 10 ml of PBS, twice in 10 ml of I00 mM glycine {pH 2.8), and twice in 10 ml of PBS. Rabbit anti-Pbx-1 serum (12 ml) was applied to the resin in a column four times. The resin was washed four times with 10 ml of PBS. Immunoglobulins were eluted by consecutive addition of ten 600-~1 volumes of 100 mM glycine (pH 2.8), and each eluted fraction was collected into a tube containing 60 ~1 of 1.0 M Tris (pH 8.05), to immediately neutralize the pH. A total yield of 1.7 mg of immunoglobulin was obtained.
Western blotting protocol
Lymphocytes were solubilized by boiling in SDS-containing Laemmli sample buffer at a concentration of 2 x 107/ml. These samples (30 ~1) were resolved by SDS-PAGE and transferred to nitrocellulose in 10 mM 3-[cyclohexylamino]-1-propanesulfonic acid {CAPS) {pH 10.8), 20% methanol, at 0.5 amp for 45 rain at 4°C. A Western blotting protocol (Promega) was followed, using 10 ~g/ml anti-Pbxl imrnunoglobulin to bind Pbxl-containing proteins and alkaline phosphatase-conjugated, goat anti-rabbit immunoglobulin to detect the location of rabbit antibodies bound to Pbxl.
Construction of expression vectors
The retroviral expression vector pGD, the parental vector of pGD210 (Daley et al. 1990 ), was obtained from Marty Scott, who had converted a non-unique XhoI site into a unique BclI site to facilitate the cloning of various cDNAs. The cDNAs of both type I and type II E2A-pbxI, encompassing sequences from the 5' end described previously (Kamps et al. 1990 ) to the unique DraI site located in both 3'-noncoding regions {residue 2851 in the type I transcript; Kamps et al. 1990) , were ligated into the BclI site, after addition of BclI linkers to the inserts. Each plasmid was transfected into NIH-3T3 cells using the calcium phosphate technique (Shih et al. 1979} .
Generation of helper-free virus
The ecotropic packaging cell line, tD-CRE, was transfected with the retroviral constructs described above. Transfected cells, selected for construct expression by growth in G418 for 2 weeks, were cloned by growth in 96-well plates from single cells and screened for expression of virus by RNA dot blot analysis. Clones expressing the most virus were expanded, and the viral titer of supematants analyzed. The titer of tD24L, a clone expressing virus encoding p85 E2A-pbxl, was 5 x 105 G418-resistance units per milliliter, whereas that of 481 S, a clone expressing virus encoding p85 E2A-Pbxl, was 5 x 10 a.
Cells, viral infections, and soft agar assays
NIH-3T3 cells were obtained from Paul Kaplan. Both normal and infected NIH-3T3 cells were grown in Dulbecco-Vogt modified Eagle medium (DMEM) containing 5% calf serum. Viral infections were performed for 2 hr in 2 ml of the same medium containing 8 ~g/ml Polybrene, then diluted to 10 ml and incubated overnight. The medium was changed the following morning. Selection for cells expressing the neomycin resistance gene (neo) was performed in DMEM containing 5% calf serum and 500 }zg/ml of G418 (Geneticin, GIBCO). Incubation with selective medium was initiated 2 days after infection. Soft agar assays were performed using 200,000 cells resuspended in DMEM containing 5% calf serum, and 0.2% Noble agar, and with a base layer of 0.6% Noble agar. Colonies were scored after 20 days. 697 cells were grown in RPMI medium supplemented with 20% fetal bovine serum, 2 mM glutamine, and 50 ~M 2-mercaptoethanol. Primary pre-B ALL cells were obtained from bone marrow aspirates of patients having t(1; 19)-positive leukemias, based on cytogenetic analysis conducted by Dr. Susana Raimondi. Leukemic cells were isolated by Ficoll-Hypaque density gradient centrifugation and viably cryopreserved in medium containing 10% dimethylsulfoxide. Each patient or patient's guardian was advised of the procedures and risks, in accordance with institutional guidelines, and gave informed consent.
Immunofluorescence NIH-3T3 cells were grown on coverslips coated with fibronectin (Sigma) as follows. Fibronectin ( 1.0 mg) was dissolved gently without vortexing in a volume of 1 ml of water at 37°C for 30 rain. Twenty milliliters of this solution was diluted to 1 ml in DMEM. Aliquots (100 ~1) of the diluted fibronectin were added directly to untreated coverslips, and incubated at 37°C for 30 rain in a tissue-culture incubator. Coverslips were rinsed with PBS twice and used immediately for growth of cells. Cells, grown on the fibronectin-treated coverslips, were prepared for immunofluorescence by fixation in 3% paraformaldehyde (pH 7.4) in PBS and permeabilized with 1.0% NP-40. E2A-Pbxl proteins were identified by incubation using a 1 : 300 dilution of anti-Pbxl serum followed by incubation with affinity-purified, rhodamine-conjugated donkey anti-rabbit antibodies (Jackson ImmunoResearch Laboratories) and visualized by fluorescence microscope as described (Van Etten et al. 1989 ).
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